Dr Reddy's launches testosterone gel in US market
06 May 2019 | News
A therapeutic equivalent generic version of AndroGel® (testosterone gel) 1.62%, approved by the U.S. Food and Drug Administration (USFDA)
image credit- reportsherald.com
Dr. Reddy’s Laboratories Ltd., along with its subsidiaries together referred to as “Dr. Reddy’s” has announced the launch of Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel® (testosterone gel) 1.62%, approved by the U.S. Food and Drug Administration (USFDA).
The AndroGel® (testosterone gel) brand and generic had U.S. sales of approximately $815.6 million MAT for the most recent twelve months ending in February 2019 according to IQVIA Health.
Dr. Reddy’s Testosterone Gel 1.62% (20.25 mg/1.25 g pump actuation) is available in a net quantity of 88 g pump which dispenses 20.25 mg of testosterone per actuation. Each metered-dose pump is capable of dispensing 60 metered pump actuations.
